Annals of Nuclear Medicine

, Volume 32, Issue 4, pp 297–301 | Cite as

68Ga-DOTATATE PET–CT imaging in carotid body paragangliomas

  • Duygu Has Şimşek
  • Yasemin Şanlı
  • Serkan Kuyumcu
  • Bora Başaran
  • Ayşe Mudun
Short Communication
  • 73 Downloads

Abstract

Objective

The aim of this study was to present our experience in the baseline evaluation of carotid body paragangliomas (CBP) with 68Ga-DOTATATE PET–CT.

Methods

Five patients (4F, 1M; age 24–73 years) with CBPs who underwent 68Ga-DOTATATE PET–CT scan before the treatment were evaluated retrospectively. PET–CT images were analyzed visually as well as semiquantitatively, with measurement of maximum standardized uptake value (SUVmax).

Results

All patients had unilateral CBP lesion, showed intense 68Ga-DOTATATE uptake in PET–CT. Additionally, 68Ga-DOTATATE avid lesions were found in two patients. One of them had focal intense uptake in thyroid gland and frontal cerebrum. The other one had intense uptake in bone and adrenal mass. Four patients were operated for unilateral primary CBP. Last patient was treated with peptide receptor radionuclide therapy (177Lu-DOTATATE) for both metastatic pheochromocytoma and CBP.

Conclusions

68Ga-DOTATATE PET–CT is a valuable imaging modality for staging of CBPs, detecting unknown lesions and changing the management of patients. It is also useful in demonstrating expression of SSTRs for PRRT opportunity.

Keywords

Carotid body paragangliomas 68Ga-DOTATATE PET–CT 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no financial or personal relationships with other people or organizations that could inappropriately influence this work.

References

  1. 1.
    Wasserman PG, Savargaonkar P. Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngol Clin North Am. 2001;34(5):845 – 62.CrossRefPubMedGoogle Scholar
  2. 2.
    Pacheco-Ojeda L. Malignant carotid body tumors: report of three cases. Ann Otol Rhinol Laryngol. 2001;110(1):36–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Sajid M, Hamilton G, Baker D. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg. 2007;34(2):127 – 30.CrossRefPubMedGoogle Scholar
  4. 4.
    Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68 Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669 – 73.CrossRefPubMedGoogle Scholar
  5. 5.
    Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of 68 Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging. 2014;4(5):426.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Kuyumcu S, Özkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, et al. Physiological and tumoral uptake of 68 Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med. 2013;27(6):538 – 45.CrossRefPubMedGoogle Scholar
  7. 7.
    Hofman MS, Lau WE, Hicks RJ. Somatostatin receptor imaging with 68 Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500 – 16.CrossRefPubMedGoogle Scholar
  8. 8.
    Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94(3):730–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49–54.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268.CrossRefPubMedGoogle Scholar
  12. 12.
    Baysal B. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39(9):617 – 22.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene. 2003;22(9):1358–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Naswa N, Kumar A, Sharma P, Bal C, Malhotra A, Kumar R. Imaging carotid body chemodectomas with 68 Ga-DOTA-NOC PET-CT. Br J Radiol. 2012;85(1016):1140–5.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sharma P, Thakar A, KC SS, Dhull VS, Singh H, Naswa N, et al. 68 Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med. 2013;54(6):841–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineŞişli Hamidiye Etfal Training and Research HospitalIstanbulTurkey
  2. 2.Department of Nuclear Medicine, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey
  3. 3.Department of Otorhinolaryngology, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey

Personalised recommendations